A randomized, phase 2 study investigating TRV130, a biased ligand of the μ-opioid receptor, for the intravenous treatment of acute pain
Eugene R. Viscusi(Thomas Jefferson University), Franck Skobieranda(Ionis Pharmaceuticals (United States)), Ruth Ann Subach, James A. Bolognese(Cytel (United States)), Michael E. Kuss(Premier Research Group), Emily Cook(New Mexico Institute of Mining and Technology), David G. Soergel(Novartis (Switzerland)), Seth Zuckerman(Cytel (United States)), Stephen Daniels(Premier Research Group), Lynn R. Webster(Adherent Technologies (United States))
Cited by 209
Related Papers
Predicting Aberrant Behaviors in Opioid-Treated Patients: Preliminary Validation of the Opioid Risk Tool
|Pain Medicine|2005|1.1k
Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Acute Pain Management From the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists
|Regional Anesthesia & Pain Medicine|2018|583
Risk Factors for Opioid-Use Disorder and Overdose
|Anesthesia & Analgesia|2017|504